Medications

Mounjaro vs Zepbound: What's the Difference?

Mounjaro and Zepbound contain exactly the same drug, tirzepatide, made by the same company. What separates them is the FDA-approved use printed on the box, the devices each brand comes in, and the price you actually pay. Here is the full comparison, straight from the two labels.

Last verified September 14, 2026·13 sources cited·Mounjaro Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Here is the short answer. Mounjaro and Zepbound are the same drug — tirzepatide, made by Eli Lilly, injected under the skin once a week. What makes them two products is the FDA-approved use printed on the carton. Mounjaro is for type 2 diabetes. Zepbound is for weight management and sleep apnea. That one difference drives everything else: which devices you can get, what your insurance will do, and how much you pay.

This guide walks through every difference that matters to someone standing at a pharmacy counter, using the two FDA labels and Eli Lilly’s own published prices as the source. It is not medical advice, and it never tells you which dose to take or whether a GLP-1 medicine is right for you. Those are conversations for you and a healthcare provider.

Are Mounjaro and Zepbound really the same drug?

Yes. Both contain tirzepatide, a single molecule that activates two hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) [1][2]. That dual action is what sets tirzepatide apart from semaglutide, the drug in Ozempic and Wegovy, which acts on the GLP-1 receptor alone.

Tirzepatide was approved first as Mounjaro, on May 13, 2022, for type 2 diabetes [3]. Eighteen months later, on November 8, 2023, FDA approved the same molecule under the name Zepbound for chronic weight management [4]. Two separate applications, two separate brand names, one active ingredient.

Both labels carry the same limitation of use: tirzepatide should not be taken alongside another tirzepatide product or any GLP-1 receptor agonist [1][2]. In practice that means you use one or the other, not both.

What is each brand actually approved for?

This is the difference that decides most of the rest.

Mounjaro is indicated, per its August 2026 label [2]:

As an adjunct to diet and exercise to improve blood sugar control in adults and children 10 years of age and older with type 2 diabetes
To reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them

The pediatric use was added on December 19, 2025, closing out a study FDA had required back in 2022 [5]. The heart indication came on August 27, 2026 [3][6].

Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity [1]:

To reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition
To treat moderate to severe obstructive sleep apnea in adults with obesity

That second indication, approved December 20, 2024, made Zepbound the first prescription medicine ever approved for obstructive sleep apnea [7].

Notice what is missing from each. Mounjaro’s label says nothing about weight loss, even though weight reduction was measured in its trials. Zepbound’s label says it is not known whether the drug is safe and effective in children [1]. Mounjaro’s covers ages 10 and up.

Do Mounjaro and Zepbound use the same doses?

The strengths are identical: 2.5, 5, 7.5, 10, 12.5 and 15 mg. How the labels talk about them differs.

Mounjaro. The label states the starting dosage is 2.5 mg once weekly. If more glycemic control is needed, the dosage may go up in 2.5 mg steps after at least four weeks on the current dose. The maximum is 15 mg once weekly in adults and 10 mg once weekly in patients 10 and older [2].

This is the one place where the two labels have actually diverged, and it happened recently. Until August 2026 the Mounjaro label said “the 2.5 mg dosage is for treatment initiation and is not intended for glycemic control” and directed an increase to 5 mg after four weeks. Supplement S-045, approved on August 27, 2026 alongside the heart indication, struck that language; FDA’s approval letter describes it as updating the label “to indicate that the 2.5 mg dose of tirzepatide can be used for ongoing glycemic control in patients with type 2 diabetes” [21]. Most secondary coverage still repeats the old rule.

Zepbound. The label states 2.5 mg once weekly for four weeks, then 5 mg, then increases of 2.5 mg after at least four weeks. It then names specific maintenance doses. For weight reduction and long-term maintenance, that is 5 mg, 10 mg or 15 mg. For obstructive sleep apnea, it is 10 mg or 15 mg. The maximum for every Zepbound indication is 15 mg [1].

One line in the Zepbound label gets misread constantly: 2.5 mg is for treatment initiation and is not approved as a maintenance dosage [1]. It exists to reduce stomach side effects during the first month. That sentence no longer has a counterpart on the Mounjaro side, as of the August 2026 change described above [21].

Missed-dose language is identical in both. If a dose is missed, the label says to take it as soon as possible within four days (96 hours). After four days have passed, skip it and go back to the regular schedule. The injection day can be changed as long as at least three days (72 hours) separate the two doses [1][2].

What devices does each brand come in?

Both brands now have four presentations on their labels, but what you can actually buy differs a lot.

	Mounjaro	Zepbound
Single-dose pen (4 per carton, needle built in)	Yes	Yes
Single-dose vial	Yes, 1-pack only	Yes, 1-pack and 4-pack
Multi-dose vial (4 doses)	Approved Jan 7, 2026	Approved Jan 7, 2026
Single-patient-use KwikPen (4 doses)	Approved Jan 20, 2026	Approved Jan 20, 2026, launched Feb 23, 2026
Sold cash-pay through LillyDirect	Single-dose pen only	Vial and KwikPen

Sources: the two current labels and Lilly’s product pages [1][2][8][9].

Both KwikPens were approved on the same day, January 20, 2026, after an unusually long road: Lilly filed the applications in late 2023, FDA sent action letters on both in January 2025, and Lilly’s complete responses did not arrive until December 2025 [10][11].

The practical difference today is availability. Lilly’s cash-pay channel sells the Zepbound vial and KwikPen but not the Zepbound single-dose pen, which goes through insurance instead [8]. For Mounjaro it is the reverse: the single-dose prefilled pen is the only presentation on the LillyDirect self-pay page [9].

Which one costs more?

There are two totally different price worlds here, and mixing them up is the fastest way to get confused.

List price (what Lilly charges wholesalers). Lilly publishes these figures on its own pricing site, drawn from AnalySource data as of January 1, 2026:

Mounjaro: $1,112.16 per fill, where a fill is a month’s supply of four pens [12]
Zepbound: $499 to $1,086.37 per fill, with a month defined as 28 days [13]

Almost nobody pays list price. It matters mainly because some savings programs are defined as a discount off it.

Cash price through LillyDirect. This is what an uninsured person, or someone whose plan excludes the drug, actually pays:

Mounjaro single-dose pen: listed at “starting at $499/month” at every strength from 2.5 mg to 15 mg [9]
Zepbound vial or KwikPen: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5, 10, 12.5 and 15 mg — but only when each refill is bought within 45 days of the previous delivery. Miss that window and the regular price applies, which Lilly publishes today as $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg [13]. The December 2025 announcement that set the $299/$399/$449 tier gave higher regular prices at the top doses — $599 for 7.5 mg, $849 for 12.5 mg and $1,049 for 15 mg [22] — and those have been superseded.

With commercial insurance. Both brands have savings cards for people whose plan covers the drug, and both can bring the cost to as little as $25 a month, with caps:

Mounjaro: up to a three-month fill for $25, with maximum savings of $150, $300 or $450 per fill and $1,950 per calendar year, up to 13 fills [15]
Zepbound single-dose pen: up to a three-month fill for $25, with maximum savings of $100, $200 or $300 per fill and $1,300 per year, up to 13 fills [14]

Both cards exclude anyone on Medicaid, Medicare, Medicare Advantage, Medigap, TRICARE, VA or DoD coverage, and both expire December 31, 2026 unless Lilly extends them [14][15].

So the honest answer to “which is cheaper” is: for cash payers, Zepbound, because Lilly built a discounted self-pay channel around it. For insured patients, it comes down to what your specific plan covers.

Do they have the same side effects and warnings?

Same molecule, so the safety picture is largely shared. Both carry an identical boxed warning: in rats, tirzepatide caused thyroid C-cell tumors, and it is unknown whether it does so in humans because the human relevance of the rodent finding has not been determined [1][2]. Both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone with a known serious hypersensitivity to tirzepatide or its ingredients [1][2].

Both labels also warn about acute pancreatitis, acute gallbladder disease, acute kidney injury from dehydration, severe gastrointestinal reactions, hypoglycemia when combined with insulin or a sulfonylurea, hypersensitivity reactions, worsening of existing diabetic retinopathy, and the risk of food entering the lungs during procedures that use anesthesia or deep sedation [1][2]. Both tell patients using oral birth control pills that the pills may work less well, and to consider a backup method for four weeks after starting and for four weeks after each dose increase [1][2].

Two things changed in 2026 that are worth knowing. In February 2026 FDA approved the removal of the suicidal ideation and behavior warning from the Zepbound label, following its review of a class-wide safety signal, and at the same time added intestinal obstruction and severe constipation including fecal impaction to the postmarketing experience section [16]. And in January 2026, when the KwikPens were approved, both labels gained a new Warnings and Precautions subsection — numbered 5.10 in the Zepbound label; Mounjaro numbers its warnings differently — saying never to share a KwikPen between patients, even if the pen needle is changed, because of the risk of transmitting blood-borne pathogens [1][2]. Both labels were revised again in late August 2026 to expand the diabetic retinopathy warning, which now directs monitoring for progression in patients with a history of diabetic retinopathy [1][2].

The most common side effects in the pooled Zepbound weight-management trials were nausea (25 to 29 percent, versus 8 percent on placebo), diarrhea (19 to 23 percent versus 8 percent), constipation (11 to 17 percent versus 5 percent) and vomiting (8 to 13 percent versus 2 percent) [1]. Mounjaro’s label lists nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain as the reactions reported in at least 5 percent of patients [2].

Why do British articles call Mounjaro a weight-loss drug?

Because in Britain, it is one. The UK’s medicines regulator authorized Mounjaro for weight management and weight loss on November 8, 2023 [17]. There is no Zepbound in the UK; Mounjaro carries both authorizations there.

That means a large amount of English-language content about “Mounjaro for weight loss” describes a label that does not exist in the United States. If you are in the US and you are being prescribed tirzepatide for weight, the brand on your prescription should be Zepbound. UK prices, pack sizes and device names also do not transfer.

How do you know a pen or vial is genuine?

Because tirzepatide is expensive and in demand, counterfeits and unapproved copies circulate. A few practical checks:

Lilly runs a free web tool at scan.lilly.com. You scan the 2D barcode printed on the outside of the carton — not the pen or vial itself, which cannot be scanned — and the site checks whether the serial number is consistent with medicine made by Lilly and obtained in the United States [18].

Lilly also warns that it has found products sold as “tirzepatide” that contained bacteria, high impurity levels, a pink color rather than the clear-to-slightly-yellow solution of the real thing, or a completely different chemical structure [19]. And tirzepatide has never been approved in pill, under-the-tongue or nasal spray form; those formulations were never studied in the trials behind Mounjaro and Zepbound [19].

FDA declared the tirzepatide shortage resolved on December 19, 2024, which removed the legal basis for mass compounding of tirzepatide copies [20]. Products still marketed as “personalized” or “tailored” tirzepatide sit outside the approved supply chain.

The bottom line

Mounjaro and Zepbound are the same medicine wearing two labels. If you have type 2 diabetes, the brand written for you will normally be Mounjaro, and since August 2026 it carries an additional claim about lowering heart attack and stroke risk. If you are being treated for obesity or for obstructive sleep apnea with obesity, the brand will be Zepbound, and Lilly has built a cash-pay channel around its vials and KwikPens that no other GLP-1 brand matches.

What you should not do is assume the two are interchangeable at the pharmacy counter. Different brand, different NDC, different device options, different savings program. Talk to your healthcare provider about which indication fits your situation, and talk to your pharmacy about which presentation your plan or your wallet can actually support.

Sources

Questions people ask

Is Mounjaro the same as Zepbound?

They contain the same active ingredient, tirzepatide, made by Eli Lilly, and both are once-weekly injections. They are not the same product on paper. Mounjaro is approved for type 2 diabetes and for lowering cardiovascular risk in adults with type 2 diabetes. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Can my doctor prescribe Mounjaro for weight loss?

Mounjaro's FDA-approved label does not include weight loss. Zepbound is the tirzepatide brand approved for that use. Prescribing decisions are between you and your healthcare provider, but insurers commonly deny diabetes-brand claims written for weight loss.

Which one is cheaper?

It depends entirely on how you pay. Lilly's cash price through LillyDirect is listed as starting at $499 a month for Mounjaro pens at every strength, versus $299 to $449 a month for Zepbound vials or KwikPens (verified 2026-09-14). If you have commercial insurance that covers the drug, both brands have savings cards that can bring the cost to as little as $25 a month.

Are the doses the same?

Both come in 2.5, 5, 7.5, 10, 12.5 and 15 mg, and both start at 2.5 mg for four weeks. The maximum on the Mounjaro label is 15 mg for adults and 10 mg for patients aged 10 to 17. Zepbound's label lists 5, 10 or 15 mg as maintenance doses for weight, and 10 or 15 mg for sleep apnea.

Can I take Mounjaro and Zepbound at the same time?

No. Both labels carry the same limitation of use: taking tirzepatide with another tirzepatide product, or with any GLP-1 receptor agonist, is not recommended.

Why do UK articles talk about Mounjaro for weight loss?

Because in Great Britain, Mounjaro carries both the diabetes and the weight-management authorization and Zepbound is not sold there. The UK regulator authorized the weight-management use in November 2023. UK prices, pack sizes and brand claims do not apply in the United States.

If I switch brands, do I start over at 2.5 mg?

That is a clinical decision for your prescriber, and neither label spells out a universal switching rule between the two brands. What does change at the pharmacy is the product name, the NDC, the device options and which savings program applies.

Do they have the same side effects?

The molecule is identical, so the safety profile overlaps heavily. Both labels carry the same boxed warning about thyroid C-cell tumors in rats and the same contraindications. The two labels number their other warnings differently, which can make them look more different than they are.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.